<![CDATA[Insights]]>https://insights.citeline.comMon, 04 Nov 2024 10:18:11 +0000en1hourly1<![CDATA[Brazil’s Hypera Unanimously Rejects EMS’ Proposed Merger ]]>https://insights.citeline.com/generics-bulletin/business/strategy/brazils-hypera-unanimously-rejects-ems-proposed-merger-CGB26QJRBBAVTD47WL3GARHHG4/https://insights.citeline.com/generics-bulletin/business/strategy/brazils-hypera-unanimously-rejects-ems-proposed-merger-CGB26QJRBBAVTD47WL3GARHHG4/Fri, 01 Nov 2024 12:22:05 +0000<![CDATA[US FDA Floats Communications Upgrade For ANDAs With Missed Goals]]>https://insights.citeline.com/generics-bulletin/policy-and-regulation/regulation/us-fda-floats-communications-upgrade-for-andas-with-missed-goals-Z67UM23UJZDJ3GCEXHZ24W6Q3E/https://insights.citeline.com/generics-bulletin/policy-and-regulation/regulation/us-fda-floats-communications-upgrade-for-andas-with-missed-goals-Z67UM23UJZDJ3GCEXHZ24W6Q3E/Fri, 01 Nov 2024 12:02:34 +0000<![CDATA[Product Or Class Guidances For Biosimilars? Industry Had Its Say]]>https://insights.citeline.com/generics-bulletin/policy-and-regulation/regulation/product-or-class-guidances-for-biosimilars-industry-had-its-say-PO57RBWGWBB3ZDTBUYMXLJFELQ/https://insights.citeline.com/generics-bulletin/policy-and-regulation/regulation/product-or-class-guidances-for-biosimilars-industry-had-its-say-PO57RBWGWBB3ZDTBUYMXLJFELQ/Fri, 01 Nov 2024 12:00:24 +0000